CU24317B1 - Conjugado de naloxol-peg cristalino - Google Patents
Conjugado de naloxol-peg cristalinoInfo
- Publication number
- CU24317B1 CU24317B1 CUP2013000047A CU20130047A CU24317B1 CU 24317 B1 CU24317 B1 CU 24317B1 CU P2013000047 A CUP2013000047 A CU P2013000047A CU 20130047 A CU20130047 A CU 20130047A CU 24317 B1 CU24317 B1 CU 24317B1
- Authority
- CU
- Cuba
- Prior art keywords
- naloxol
- crystal
- peg conjugate
- salt forms
- formula
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C07D489/04—Salts; Organic complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Emergency Medicine (AREA)
- Compression Or Coding Systems Of Tv Signals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38850110P | 2010-09-30 | 2010-09-30 | |
| PCT/SE2011/051161 WO2012044243A1 (fr) | 2010-09-30 | 2011-09-29 | Conjugué cristallin de naloxol-peg |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20130047A7 CU20130047A7 (es) | 2013-08-29 |
| CU24317B1 true CU24317B1 (es) | 2018-02-08 |
Family
ID=45893441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2013000047A CU24317B1 (es) | 2010-09-30 | 2011-09-29 | Conjugado de naloxol-peg cristalino |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9012469B2 (fr) |
| EP (2) | EP2992903B8 (fr) |
| JP (1) | JP6034789B2 (fr) |
| KR (1) | KR101791724B1 (fr) |
| CN (1) | CN103237547B (fr) |
| AR (1) | AR083268A1 (fr) |
| AU (1) | AU2011307608B8 (fr) |
| BR (1) | BR112013007113B1 (fr) |
| CA (1) | CA2812649C (fr) |
| CL (1) | CL2013000866A1 (fr) |
| CO (1) | CO6700851A2 (fr) |
| CR (1) | CR20130146A (fr) |
| CU (1) | CU24317B1 (fr) |
| DK (1) | DK2621496T4 (fr) |
| EA (1) | EA023929B1 (fr) |
| EC (1) | ECSP13012531A (fr) |
| ES (2) | ES2562643T5 (fr) |
| GT (1) | GT201300084A (fr) |
| HK (1) | HK1187248A1 (fr) |
| HR (1) | HRP20151420T4 (fr) |
| HU (1) | HUE026726T2 (fr) |
| IL (1) | IL225308A0 (fr) |
| ME (1) | ME02313B (fr) |
| MX (1) | MX2013003587A (fr) |
| MY (1) | MY173890A (fr) |
| NI (1) | NI201300034A (fr) |
| NZ (1) | NZ609874A (fr) |
| PE (1) | PE20140636A1 (fr) |
| PL (1) | PL2621496T5 (fr) |
| PT (1) | PT2621496E (fr) |
| RS (1) | RS54488B8 (fr) |
| SA (1) | SA111320808B1 (fr) |
| SG (1) | SG188474A1 (fr) |
| SI (1) | SI2621496T2 (fr) |
| SM (1) | SMT201600004B (fr) |
| TW (1) | TWI518088B (fr) |
| UA (1) | UA112847C2 (fr) |
| UY (1) | UY33643A (fr) |
| WO (1) | WO2012044243A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012469B2 (en) | 2010-09-30 | 2015-04-21 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
| PL2914599T3 (pl) * | 2012-10-30 | 2018-05-30 | Nektar Therapeutics | Stałe postacie soli alfa-6-MPEG6-O-hydroksykodonu jako agoniści opioidowi i ich zastosowania |
| CN107660207B (zh) * | 2015-03-10 | 2020-09-29 | 罗德科技公司 | 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 |
| CN107033154B (zh) * | 2016-02-02 | 2020-02-04 | 上海瀚迈生物医药科技有限公司 | 阿片受体拮抗剂缀合物及其应用 |
| CN107033155B (zh) * | 2016-02-04 | 2019-04-26 | 国药集团国瑞药业有限公司 | 一种吗啡酮类化合物的立体选择性还原方法 |
| EP3228307A1 (fr) | 2016-04-05 | 2017-10-11 | Sandoz Ag | Solid dispersion contenant des antagonistes opioides |
| CN107303392A (zh) * | 2016-04-19 | 2017-10-31 | 石家庄蒎格医药科技有限公司 | 一种聚乙二醇-纳洛酮组合物及应用 |
| US11077103B2 (en) * | 2016-11-23 | 2021-08-03 | Aurobindo Pharma Ltd. | Naloxegol oxalate and solid dispersion thereof |
| US11373198B2 (en) * | 2016-12-02 | 2022-06-28 | Honda Motor Co., Ltd. | Evaluation device, evaluation method, and evaluation program |
| WO2019058387A1 (fr) * | 2017-09-19 | 2019-03-28 | Msn Laboratories Private Limited, R&D Center | Procédé amélioré de préparation de (5α,6α)-17-allyl-6-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy) -4,5-époxymorphinane-3,14-diol et de ses sels pharmaceutiquement acceptables |
| CN114137133B (zh) * | 2021-12-03 | 2023-06-09 | 北京尚修堂医药科技有限公司 | 一种纳洛醇-peg衍生物有关物质的检测方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2507136A (en) | 1949-02-19 | 1950-05-09 | New York Quinine And Chemical | Alkaloid purification |
| EP0668764A1 (fr) * | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Procedes d'identification et d'utilisation d'analgesiques opioides de faible dependance ou de non dependance |
| EP1037649B1 (fr) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| EP0995757A3 (fr) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibiteurs bivalentes de la proteasome |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| JP4861586B2 (ja) | 1999-12-22 | 2012-01-25 | ネクター セラピューティックス | 水溶性ポリマーの立体的に妨害される誘導体 |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| WO2001062299A2 (fr) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Conjugues polymeres hydrosolubles d'acide artelinique |
| US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
| JP2004514701A (ja) | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル，コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
| PT1349855E (pt) | 2000-12-22 | 2006-12-29 | Smithkline Beecham Plc | Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona |
| CA2437989A1 (fr) | 2001-02-20 | 2002-08-29 | Enzon, Inc. | Lieurs polymeres a terminaisons ramifiees, et conjugues polymeres en contenant |
| US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6756354B2 (en) | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
| CA2463938C (fr) | 2001-10-18 | 2011-08-09 | Nektar Therapeutics Al, Corporation | Conjugues polymeres d'antagonistes opioides |
| EP1441772A2 (fr) | 2001-10-29 | 2004-08-04 | Nektar Therapeutics Al, Corporation | Conjugues polymeres d'inhibiteurs de proteine kinease c |
| ATE359829T1 (de) | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
| ES2733044T1 (es) | 2002-04-05 | 2019-11-27 | Mundipharma Pharmaceuticals S L | Composición farmacéutica que contiene oxicodona y naloxona |
| GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| CA2547140A1 (fr) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Erythropoietine glycopegylee |
| CA2758460C (fr) | 2003-12-16 | 2014-09-23 | Nektar Therapeutics | Methodes de preparation de compositions de reactifs oligo (ethylene glycol) monodisperses |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| US8320574B2 (en) * | 2006-04-20 | 2012-11-27 | Hewlett-Packard Development Company, L.P. | Methods and systems for reducing acoustic echoes in communication systems |
| NZ572252A (en) | 2006-04-21 | 2011-09-30 | Nektar Therapeutics | Stereoselective reduction of a morphinone |
| MX2009004965A (es) * | 2006-11-07 | 2009-06-05 | Nektar Therapeutics Al Corp | Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides. |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| BRPI0912219A2 (pt) | 2008-05-07 | 2015-10-06 | Nektar Therapeutics | método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. |
| CA2768392C (fr) | 2009-07-21 | 2018-04-17 | Nektar Therapeutics | Conjugues oligomeres-agonistes opioides |
| US9012469B2 (en) | 2010-09-30 | 2015-04-21 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
-
2011
- 2011-09-29 US US13/823,953 patent/US9012469B2/en active Active
- 2011-09-29 MY MYPI2013700499A patent/MY173890A/en unknown
- 2011-09-29 JP JP2013531533A patent/JP6034789B2/ja active Active
- 2011-09-29 WO PCT/SE2011/051161 patent/WO2012044243A1/fr active Application Filing
- 2011-09-29 KR KR1020137008014A patent/KR101791724B1/ko active IP Right Grant
- 2011-09-29 EA EA201300423A patent/EA023929B1/ru unknown
- 2011-09-29 EP EP15188944.1A patent/EP2992903B8/fr active Active
- 2011-09-29 AU AU2011307608A patent/AU2011307608B8/en active Active
- 2011-09-29 HU HUE11829686A patent/HUE026726T2/en unknown
- 2011-09-29 ES ES11829686T patent/ES2562643T5/es active Active
- 2011-09-29 ES ES15188944T patent/ES2819305T3/es active Active
- 2011-09-29 PL PL11829686T patent/PL2621496T5/pl unknown
- 2011-09-29 ME MEP-2015-217A patent/ME02313B/me unknown
- 2011-09-29 SI SI201130699T patent/SI2621496T2/sl unknown
- 2011-09-29 BR BR112013007113-3A patent/BR112013007113B1/pt active IP Right Grant
- 2011-09-29 CN CN201180057584.0A patent/CN103237547B/zh active Active
- 2011-09-29 PE PE2013000652A patent/PE20140636A1/es active IP Right Grant
- 2011-09-29 NZ NZ609874A patent/NZ609874A/en unknown
- 2011-09-29 EP EP11829686.2A patent/EP2621496B2/fr active Active
- 2011-09-29 SG SG2013017447A patent/SG188474A1/en unknown
- 2011-09-29 RS RS20150876A patent/RS54488B8/sr unknown
- 2011-09-29 DK DK11829686.2T patent/DK2621496T4/en active
- 2011-09-29 CA CA2812649A patent/CA2812649C/fr active Active
- 2011-09-29 PT PT118296862T patent/PT2621496E/pt unknown
- 2011-09-29 UA UAA201303320A patent/UA112847C2/uk unknown
- 2011-09-29 MX MX2013003587A patent/MX2013003587A/es active IP Right Grant
- 2011-09-29 CU CUP2013000047A patent/CU24317B1/xx unknown
- 2011-09-30 TW TW100135672A patent/TWI518088B/zh active
- 2011-09-30 UY UY0001033643A patent/UY33643A/es not_active Application Discontinuation
- 2011-09-30 AR ARP110103631A patent/AR083268A1/es not_active Application Discontinuation
- 2011-10-01 SA SA111320808A patent/SA111320808B1/ar unknown
-
2013
- 2013-03-18 IL IL225308A patent/IL225308A0/en active IP Right Grant
- 2013-03-27 EC ECSP13012531 patent/ECSP13012531A/es unknown
- 2013-03-28 CL CL2013000866A patent/CL2013000866A1/es unknown
- 2013-04-01 CR CR20130146A patent/CR20130146A/es unknown
- 2013-04-01 NI NI201300034A patent/NI201300034A/es unknown
- 2013-04-01 GT GT201300084A patent/GT201300084A/es unknown
- 2013-04-08 CO CO13090985A patent/CO6700851A2/es unknown
-
2014
- 2014-01-09 HK HK14100217.1A patent/HK1187248A1/zh active IP Right Maintenance
-
2015
- 2015-03-11 US US14/645,347 patent/US9149539B1/en active Active
- 2015-12-28 HR HRP20151420TT patent/HRP20151420T4/hr unknown
-
2016
- 2016-01-05 SM SM201600004T patent/SMT201600004B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24317B1 (es) | Conjugado de naloxol-peg cristalino | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| CO6640270A2 (es) | Morfolinopirimidad y su uso en terapia | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| WO2014152389A8 (fr) | Agent d'imagerie permettant de détecter des cellules malades | |
| GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| UA113541C2 (xx) | Заміщені піролідин-2-карбоксаміди | |
| BRPI0911422B8 (pt) | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos | |
| CU24272B1 (es) | Derivados de tetrahidropirido-pirimidina como inhibidores de mek | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| CR20110562A (es) | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| ECSP14013215A (es) | Compuestos novedosos | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| CR10654A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados | |
| CO6920294A2 (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| UY32704A (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| EA201591024A1 (ru) | Димерные соединения | |
| SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
| CO6640301A2 (es) | Compuestos ologo-benzamida y su uso | |
| EA201391198A1 (ru) | Несмываемая, нетвердая, кондиционирующая кожу композиция, которая имеет диспергирующую масляную фазу и содержит 12-гидроксистеариновую кислоту | |
| GT201200066A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |